PARP1 and neoplasm: A recent Phase 1/2 trial on neuroendocrine cancers using ATR inhibitors in conjunction with sacituzumab govitecan (Trodelvy), an antibody–drug conjugate that couples an antibody for Trop-2 to the topoisomerase inhibitor SN-38, showed tumor regression in two CRPC-NE patients (NCT04826341) and this study is now being extended to include PARP inhibitor-resistant HRD tumors [173].